Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Kazia Therapeutics jumped 51.74% in after-hours trading Tuesday after reporting a rare immune-complete response in a patient.

The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults with post- and precapillary pulmonary hypertension due to heart failure. The Rahway, N.J., ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Merck has agreed to acquire Cidara Therapeutics, a biotech company developing a drug designed to prevent the flu.